312 related articles for article (PubMed ID: 24690100)
41. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010.
Gao YJ; Pan C; Tang JY; Lu FJ; Chen J; Xue HL; Zhai XW; Li J; Ye QD; Zhou M; Wang HS; Miao H; Qian XW; Xu Z; Meng JH
Pediatr Blood Cancer; 2014 Apr; 61(4):659-63. PubMed ID: 24243691
[TBL] [Abstract][Full Text] [Related]
43. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
44. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis.
Zhu YM; Zhao WL; Fu JF; Shi JY; Pan Q; Hu J; Gao XD; Chen B; Li JM; Xiong SM; Gu LJ; Tang JY; Liang H; Jiang H; Xue YQ; Shen ZX; Chen Z; Chen SJ
Clin Cancer Res; 2006 May; 12(10):3043-9. PubMed ID: 16707600
[TBL] [Abstract][Full Text] [Related]
45. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
46. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Pichler H; Reismüller B; Steiner M; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Panzer-Grümayer R; Haas OA; Attarbaschi A; Mann G;
Br J Haematol; 2013 May; 161(4):556-65. PubMed ID: 23480776
[TBL] [Abstract][Full Text] [Related]
47. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
48. Extended triple intrathecal therapy in children with T-cell acute lymphoblastic leukaemia: a report from the Israeli National ALL-Studies.
Stark B; Avrahami G; Nirel R; Abramov A; Attias D; Ballin A; Bielorai B; Burstein Y; Gavriel H; Elhasid R; Kapelushnik J; Sthoeger D; Toren A; Wientraub M; Yaniv I; Izraeli S
Br J Haematol; 2009 Oct; 147(1):113-24. PubMed ID: 19694717
[TBL] [Abstract][Full Text] [Related]
49. Update on biology and treatment of T-cell acute lymphoblastic leukaemia.
Patrick K; Vora A
Curr Opin Pediatr; 2015 Feb; 27(1):44-9. PubMed ID: 25502893
[TBL] [Abstract][Full Text] [Related]
50. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A
Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978
[TBL] [Abstract][Full Text] [Related]
51. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.
Mirandola L; Chiriva-Internati M; Montagna D; Locatelli F; Zecca M; Ranzani M; Basile A; Locati M; Cobos E; Kast WM; Asselta R; Paraboschi EM; Comi P; Chiaramonte R
J Pathol; 2012 Apr; 226(5):713-22. PubMed ID: 21984373
[TBL] [Abstract][Full Text] [Related]
52. Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols.
Andersen MK; Autio K; Barbany G; Borgström G; Cavelier L; Golovleva I; Heim S; Heinonen K; Hovland R; Johannsson JH; Johansson B; Kjeldsen E; Nordgren A; Palmqvist L; Forestier E
Br J Haematol; 2011 Oct; 155(2):235-43. PubMed ID: 21902680
[TBL] [Abstract][Full Text] [Related]
53. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
54. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15.
Inukai T; Kiyokawa N; Campana D; Coustan-Smith E; Kikuchi A; Kobayashi M; Takahashi H; Koh K; Manabe A; Kumagai M; Ikuta K; Hayashi Y; Tsuchida M; Sugita K; Ohara A
Br J Haematol; 2012 Feb; 156(3):358-65. PubMed ID: 22128890
[TBL] [Abstract][Full Text] [Related]
56. The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.
Paganin M; Grillo MF; Silvestri D; Scapinello G; Buldini B; Cazzaniga G; Biondi A; Valsecchi MG; Conter V; Te Kronnie G; Basso G
Br J Haematol; 2018 Sep; 182(5):705-711. PubMed ID: 29938780
[TBL] [Abstract][Full Text] [Related]
57. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.
Kox C; Zimmermann M; Stanulla M; Leible S; Schrappe M; Ludwig WD; Koehler R; Tolle G; Bandapalli OR; Breit S; Muckenthaler MU; Kulozik AE
Leukemia; 2010 Dec; 24(12):2005-13. PubMed ID: 20944675
[TBL] [Abstract][Full Text] [Related]
58. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
59. NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.
Kimura S; Seki M; Yoshida K; Shiraishi Y; Akiyama M; Koh K; Imamura T; Manabe A; Hayashi Y; Kobayashi M; Oka A; Miyano S; Ogawa S; Takita J
Cancer Sci; 2019 Feb; 110(2):784-794. PubMed ID: 30387229
[TBL] [Abstract][Full Text] [Related]
60. Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 protocol.
Kuchinskaya E; Heyman M; Nordgren A; Söderhäll S; Forestier E; Wehner P; Vettenranta K; Jonsson O; Wesenberg F; Sahlén S; Nordenskjöld M; Blennow E
Br J Haematol; 2011 Mar; 152(5):615-22. PubMed ID: 21241277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
